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Abstract
We recently demonstrated that the respiratory syncytial virus (RSV) NS1 protein, an antagonist of host type I interferon (IFN-
I) production and signaling, has a suppressive effect on the maturation of human dendritic cells (DC) that was only partly
dependent on released IFN-I. Here we investigated whether NS1 affects the ability of DC to activate CD8+ and CD4+ T cells.
Human DC were infected with RSV deletion mutants lacking the NS1 and/or NS2 genes and assayed for the ability to
activate autologous T cells in vitro, which were analyzed by multi-color flow cytometry. Deletion of the NS1, but not NS2,
protein resulted in three major effects: (i) an increased activation and proliferation of CD8+ T cells that express CD103, a
tissue homing integrin that directs CD8+ T cells to mucosal epithelial cells of the respiratory tract and triggers cytolytic
activity; (ii) an increased activation and proliferation of Th17 cells, which have recently been shown to have anti-viral effects
and also indirectly attract neutrophils; and (iii) decreased activation of IL-4-producing CD4+ T cells - which are associated
with enhanced RSV disease - and reduced proliferation of total CD4+ T cells. Except for total CD4+ T cell proliferation, none
of the T cell effects appeared to be due to increased IFN-I signaling. In the infected DC, deletion of the NS1 and NS2 genes
strongly up-regulated the expression of cytokines and other molecules involved in DC maturation. This was partly IFN-I-
independent, and thus might account for the T cell effects. Taken together, these data demonstrate that the NS1 protein
suppresses proliferation and activation of two of the protective cell populations (CD103+ CD8+ T cells and Th17 cells), and
promotes proliferation and activation of Th2 cells that can enhance RSV disease.
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Introduction
Following the identification of the NS1 protein of influenza A
virus as a type I interferon (IFN-I)-antagonist more than a decade
ago [1], such proteins have been identified for many viruses. Their
effects on the innate immune system include interference with
IFN-I induction, IFN-I-activated signaling, and components of the
IFN-I-induced antiviral state (reviewed in [2]). The effects of viral
IFN-I antagonists on the adaptive immune response are, however,
largely unexplored. Meanwhile, IFN-I is known to have profound
effects on key individual components of the adaptive immune
system. These effects are diverse and may include both stimulatory
and inhibitory roles. For example, several studies have shown that
IFN-I promotes maturation of dendritic cells (DC) (reviewed in
[3]), although one study demonstrated an inhibitory effect on
mouse Langerhans cells, which are DC located in the epidermis
[4]. The effect of IFN-I on T cells is also quite complex and
depends on various factors including the type of T cells (such as
CD8+, CD4+ Th1, or CD4+ Th2), their stage of development, the
concentration of IFN-I [5], the experimental system used, and
innate inflammatory signals produced during infection, which can
be different across various pathogens [6]. For example, while some
studies demonstrated that IFN-I stimulates activation and
proliferation of T cells [7,8,9,10], others demonstrated an
inhibitory effect [11,12,13,14]. In the case of RSV, IFN-I has
been demonstrated to inhibit proliferation of CD4+ T cells in vitro
[15]. Thus, the net effect of viral IFN-I antagonist proteins on the
adaptive immune response is difficult to predict since it may be the
outcome of opposing (i.e. stimulatory and inhibitory) effects of
IFN-I on various individual components of the adaptive immune
system.
RSV continues to be the most important viral agent of severe
respiratory tract illness in infants and children worldwide and is an
important cause of morbidity and mortality in the elderly and
severely immunocompromised individuals (reviewed in [16,17]).
An unusual feature of RSV is its capability to re-infect
symptomatically (albeit with reduced disease) throughout life
without significant antigenic change [18,19], suggesting an ability
of the virus to partially suppress or evade the host’s adaptive
immune response. Several mechanisms contributing to immune
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expression of the secreted form of RSV G protein, one of the two
major neutralization antigens of RSV, which prevents efficient
antibody mediated neutralization of the virus [20]. Furthermore,
the RSV NS1 and NS2 accessory proteins are known to inhibit the
production of IFN-I and type III interferon, and to inhibit
signaling resulting from the engagement of the IFN-I receptor
(IFNAR) [21,22,23,24,25,26]. The two proteins also were
demonstrated to inhibit apoptosis [27]. Previously, we analyzed
the effect of the NS1 and NS2 proteins on stimulation of human
DC by RSV. We reported that the NS1 protein suppresses DC
maturation, which was only partly due to suppression of the IFN-I
response; furthermore, this effect was somewhat enhanced by the
added deletion of the NS2 protein, whereas deletion of NS2 alone
had no effect [28].
In the present study, we extend these findings by evaluating the
role of the NS1 and NS2 proteins in RSV-specific human T cell
responses by co-culturing primary human CD4+ or CD8+ T cells
with autologous immature monocyte-derived DC that had been
infected with recombinant RSVs lacking the NS1 and/or NS2
proteins. DC derived from primary human monocytes represent
an appropriate model for lung-infiltrating DC, since monocytes
give rise to mucosal DC [29], which are highly relevant to the
immune response to RSV that occurs in pulmonary mucosa [30].
Moreover, inflammation is a typical feature of acute infections
with RSV and other respiratory viruses, and monocyte-derived
DC are phenotypically and functionally similar to DC located at
sites of inflammation in vivo [31]. Another important advantage of
the human DC-T cell co-cultivation system is that it avoids
limitations of the commonly used mouse model for RSV, which is
based on a non-natural host that is only semi-permissive for RSV
infection. Mice also have some incongruities in their immune
system compared to humans; for example, IFN-I activates human
and mouse T cells by different mechanisms [32,33]. In the present
study, we identified three major effects of the NS1 protein on T
cells that likely play a role in reducing the efficiency of the adaptive
immune response to RSV and may contribute to disease severity.
We also investigated the role of IFN-I in regulating these effects.
Results
Co-culture of virus-infected human DC with autologous
CD4+ and CD8+ T cells
We investigated the effects of the RSV NS1 and NS2 proteins
on the ability of human monocyte-derived DC to activate
autologous T cells during co-culture in vitro (Fig. 1). DC were
infected with 2 plaque forming units (PFU) per cell of wt RSV or
RSV that lacks the NS1, NS2, or both genes and expresses
enhanced green fluorescent protein (GFP) (DNS1, DNS2, DNS1/2
[28]). The DC were washed and co-cultured with purified
autologous CD8+ or CD4+ T cells and incubated for 7 days
(Fig. 1A). The T cells were then immunostained for surface
markers and intracellular cytokines and analyzed by multi-color
flow cytometry (Fig. 1B). Flow cytometry data were analyzed for (i)
proliferated CD8+ or CD4+ T cells measured by dilution of
carboxyfluorescein diacetate succinimidyl ester (CFSE) intensity
due to cell division, (ii) proliferated CD8+ or CD4+ T cells positive
for each individual marker, and (iii) proliferated T cell populations
positive for one or more markers and negative for the other
markers, resulting in a total of 32 combinations (Fig. 1B). Since
essentially all adults have been exposed to RSV due to prior
natural infections, the proliferating T cells would primarily
represent activation of memory cells. The possible presence of
trace numbers of RSV-specific naı ¨ve T cells would not affect the
study. We note that viruses lacking the NS1 and/or NS2 proteins
are similar to wt virus with regard to their efficiency of infection of
human DCs and have only a modest reduction in viral gene
expression [28]. Thus, changes in immune cells associated with the
deletions (below) can be attributed to the absence of the NS1/2
genes rather than substantial changes in viral growth or gene
expression.
The NS1 protein suppresses the activation of CD8+ T cells
positive for the mucosal tissue homing molecule CD103
(aEb7 integrin)
Co-cultivation of wt RSV-infected DC with CD8+ T cells
resulted in significant proliferation of T cells, which was negligible
withmock-infected DC(Fig.2).AscomparedtowtRSV,deletion of
the NS1 gene resulted in an increased proliferation of CD8+ T cells
using cells from 6 donors and reduced proliferation with cells from 4
donors. Deletion of the NS2 gene resulted in an increased
proliferation of cells from only 2 of 10 donors (Fig. 2). On average,
deletion of the NS1, NS2, and NS1 and NS2 together resulted in an
increase in mean CD8+ T cell proliferation of 20, 13 and 17%,
respectively, as compared to wt RSV, and none of these differences
were significant. Thus, the effect of NS1 and/or NS2 deletion on
total CD8+ T cell activation was modest and inconsistent.
We then evaluated the effects of the NS1 and NS2 deletions on
activation of specific subsets of CD8+ T cells by multicolor flow
cytometry. The analysis involved staining for two T cell surface
proteins: CD103 (the aE subunit of the aEb7 integrin), which is
preferentially expressed by CD8+ T lymphocytes present in
mucosal tissue, directs lymphocytes to mucosal tissues by binding
to the epithelial cell marker E-cadherin [34,35,36], and triggers
cytolytic activity of CD8+ T cells in lung tissue [37], and CD107a,
which is a marker of de-granulation of CD8+ CTL [38]. We also
analyzed intracellular staining of the cytokines IFNc, IL-2, and
TNFa, which are considered markers of CD8+ CTL activation
[39]. We found that deletion of the NS1 gene alone or in
combination with the NS2 gene resulted in a dramatic increase in
the number of proliferating CD8+ cells that express CD103
(Fig. 3A, panel I). In addition to this increase in the number of
CD103+ cells, deletion of NS1 and NS1/2 was also accompanied
by an increase in the median fluorescence intensity (MFI) of
CD103 expression of up to 32% as compared to wt RSV, an
increase that was statistically significant in most, but not all cases
(Fig. S1A). In addition, deletion of NS1 or NS1/2 resulted in a
mean increase of 30% and 58%, respectively, in total CD8+ T
cells positive for CD107a, although in case of the NS1 deletion, the
Author Summary
Respiratory syncytial virus (RSV) is a leading cause of
pediatric lower respiratory tract disease. RSV has two IFN-I
antagonist proteins, NS1 and NS2. In this study, we
infected primary human dendritic cells with recombinant
RSV from which the NS1 and/or the NS2 genes were
deleted, and evaluated effects on the proliferation of
autologous T lymphocytes during co-culture in vitro.W e
found that NS1, but not NS2, has a suppressive effect on
two cell populations, namely CD103+ CD8+ T cells and
Th17 cells, which are known to protect against viral
respiratory infections, and a stimulatory effect on Th2 cells,
which are involved in enhanced disease caused by RSV. We
also provide evidence that these effects are not due to
suppressed IFN-I production or signaling in dendritic cells
or T cells, and that they likely result from reduced
maturation of dendritic cells caused by the NS1 protein.
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presence of this degranulation marker presumably is a conse-
quence of cytotoxic activity of CD8+ T cells against the DC in the
co-culture, and thus is a marker for activation. Incidentally,
cytotoxic attack on DC is not necessarily an aberrant activity, and
indeed has been suggested to occur in vivo as a means of down-
regulating further T cell activation [40]. It also should be noted
that CD107a transiently appears on cell surface and is rapidly
Figure 1. Co-cultivation of human DC and T cells and multi-color flow cytometetry analysis of T cells. A. Co-cultivation of human DC
pre-infected with wt RSV and its NS1/2 deletion mutants with autologous CD8+ or CD4+ T cells. Immature DC were generated in vitro from peripheral
blood monocytes and were labeled with CellVue Lavender dye or DDAO. CD8+ and CD4+ T cells were purified from elutriated lymphocytes from the
same donors by negative and positive selection, respectively. DC were inoculated with wt RSV or the NS1/2 deletion mutants (MOI of 2 PFU/cell), SEB-
treated, or mock-treated for 4 h, and co-cultured with purified CFSE-labeled CD8+ or CD4+ T cells for 7 days. Co-culture supernatants were analyzed
for the indicated cytokines by ELISA, and the T cells were stained for the indicated cytokines and activation markers followed by multicolor flow
cytometry. B. Gating and analysis of CD8+ and CD4+ T cells by flow cytometry. The selected cell subset of each stage is outlined in red: gate 1, live/
dead staining versus DC labels (CellVue Lavender or DDAO) to eliminate DC and dead T cells; gate 2, live/dead staining versus CD3 to obtain live
CD3+ T cells; gate 3, CD8 versus CD3 (made for only CD8+ T cells) to ensure the CD3+CD8+ phenotype of the CD8+ T cells; gate 4, forward scatter
height versus forward scatter area to obtain an unclustered single cell population; gate 5, side scatter area versus forward scatter area to examine cell
size and granularity; and gate 6, CD3 versus CFSE to obtain proliferated CD3+ T cells, as detected by dilution of CFSE due to cell divisions. Proliferated
T cells were then analyzed for the expression of individual activation markers and intracellular cytokines and also for sub-populations expressing
various combinations of them by Boolean gating using FlowJo software.
doi:10.1371/journal.ppat.1001336.g001
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CD107a observed on day 7 probably is a substantial underesti-
mate of the total amount of degranulation occurring during the 7
day incubation. Deletion of NS1 or NS1/2 also resulted in
substantial increases in CD8+ cells that were positive for CD103
plus IFNc (Fig. 3A, panel III and 3B) and CD103 plus both IFNc
and IL-2 (Fig. 3A, panel IV). In contrast, deletion of the NS2 gene
alone did not alter the expression of these various markers.
Incidentally, deletion of NS1, but not NS2, also was associated
with a down-regulation of the number of total CD8+ T cells
secreting TNFa in most of the donors (Fig. 3A, panel V). As a
possible explanation of this effect, deletion of NS1 is associated
with increased secretion of IFN-I by RSV-infected DC [28], and
IFN-I has been shown to suppress the production of TNFa [42].
Data are conflicting as to whether TNFa plays a role in CD8+
CTL-mediated lysis of target cells [43,44]. Perhaps more
importantly, TNFa down-regulates memory CD8+ T cell
responses by limiting the duration of the CTL effector phase
and magnitude of CD8 T cell memory response [45].
Taken together these data suggest that the RSV NS1 protein
reduces the number of CD8+ T cells positive for the mucosal tissue
homing molecule CD103, reduces activation of these cells, as
measured by expression of the de-granulation marker CD107a
and IFNc, and increases the number of CD8+ T cells positive for
TNFa.
The NS1 protein skews the phenotype of CD4+ T cells
towards Th2 and reduces activation and proliferation of
Th17 and Th17/Th1 cells
We also evaluated the effects of deleting the NS1 and NS2
proteins on the activation of CD4+ T cells using the co-culture
system. First, we compared the levels of proliferation of total
CD4+ T cells following co-culture with autologous DC pre-
infected with wt RSV or the NS1 and/or NS2 deletion mutants
using the same experimental design as that used for CD8+ T cells
(Fig. 1). Abundant proliferation of RSV-specific CD4+ T cells was
detected by CFSE dilution assay when the cells were co-cultivated
with DC pre-infected with wt RSV, whereas there was a near-
absence of proliferation in response to mock-infected DC (Fig. 4).
Deletion of the NS1 gene resulted in a significant reduction in the
proliferation of CD4+ T cells (Fig. 4A, B): the effect was observed
in all samples and mean reduction associated with deletion of the
NS1 and NS1/2 genes was 26% and 22%, respectively. In
contrast, deletion of the NS2 gene alone was associated with no
change or only a marginal reduction of proliferation (Fig. 4A).
Thus, the NS1 protein, but not NS2, promotes CD4+ T cell
proliferation.
We also investigated the effects of the NS1 and NS2 proteins on
the cytokine profiles of proliferating CD4+ T cells from the co-
culture experiments described above by intracellular cytokine
staining of T cells and multi-color flow cytometry. The analyzed
cytokines included markers for the Th1 (IFNc), Th2 (IL-4), and
Th17 (IL-17) subsets, as well as general markers of activation (IL-2
and TNFa). Unexpectedly, we found a sizable population of
CD4+ T cells positive for both IFNc and IL-4, which made up
12.6% of total CD4+ T cells proliferating in response to
stimulation with wt RSV-infected DC and also accounted for
most of the IL-4+ population (Fig. 5A, B). CD4+ T cells positive
for both IFNc and IL-4 were previously identified in mice and
have been cloned and characterized in vitro [46]. A recent study
demonstrated that infection of mice with lymphocytic choriomen-
ingitis virus reprogrammed otherwise stably committed Th2 cells
to adopt an IL-4+IFNc+ ‘‘Th2+1’’ phenotype that was maintained
in vivo for months [47]. However, to the best of our knowledge a
similar human Th cell population has not yet been reported [48].
In the present study, control experiments excluded the possibility
that the Th1/Th2 phenotype of CD4+ T cells was the result of
fluorochrome spectral overlap: specifically, the IL-4+ IFNc+
double positive cells were observed only with antibodies to both
IFNc and IL-4 and were not observed when the cells were stained
with all antibodies while omitting those for IFNc or IL-4
(Materials and Methods and Fig. S2B).
Deletion of the NS1 gene alone or with the NS2 gene, but not
deletion of NS2 alone, resulted in a significant reduction in the
number of cells secreting IL-4, including total IL-4+ cells and those
positive for both IL-4 and IFNc (Fig. 5A, B) in most of the donors.
Furthermore, analysis of IL-4 expression showed that deletion of
NS1, but not NS2, also resulted in reduced IL-4 MFI for total IL-
4+ as well as IL-4+IFNc+ cells (Fig. S1B). No change was observed
in the total number of IFNc or IL-2 secreting cells (not shown).
These results suggest that the NS1 protein acts as a factor
promoting the Th2 response, acting to both shift the bias toward
Th2 and to promote proliferation. The reduced percentages of not
only IL-4+ but also IL-4+IFNc+ cells are consistent with our
previous studies demonstrating that the induction of a Th2
Figure 2. Proliferation of CD8+ T cells during co-cultivation
with autologous DC that had been pre-infected with wt RSV or
its NS1/2 deletion mutants. A. Extent of CD8+ T cell proliferation in
response to co-culture with DC pre-infected with wt RSV or the NS1/2
deletion mutants, normalized to results with wt RSV assigned the value
of 100% (dotted line). A total of 10 donors were analyzed, indicated
individually by symbols, with all viruses compared in parallel for each
donor. The horizontal bars represent the mean values. For wt RSV, the
mean extent of CD8+ T cell proliferation (7.2%) is expressed as a
percentage of the total CD8+ T cell population. No statistically
significant difference between T cells co-cultivated with DC infected
with various viruses was found. B. Example of primary flow cytometry
data using cells from one representative donor; the percentage of each
proliferated population is indicated.
doi:10.1371/journal.ppat.1001336.g002
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production of not only the Th2 cytokines, but also of the Th1
cytokine IFNc [49], as well as the observation by others that the
increased production of Th2 cytokines in atopic children is not
associated with a reduced level of IFNc [50].
Deletion of the NS1 gene or both the NS1 and NS2 genes, but
not deletion of NS2 alone, also resulted in elevated levels of total
IL-17+ cells, as compared to the levels associated with wt RSV, by
125% and 33%, respectively (Fig. 5C, D). Interestingly, we
detected a substantial population of the recently described human
Th17/Th1 cells positive for both IL-17 and IFNc [51], and
confirmed their double positive phenotype by staining with all
antibodies while omitting those for IFNc or IL-17 (Fig. S2C). The
percentage of this cell population was also increased due to
deletion of NS1 or both the NS1 and NS2 genes, and the increases
were even more dramatic than for total IL-17+ cells, 233% and
64%, respectively. These data indicate that the NS1 protein also
antagonizes or alters the adaptive immune response by suppressing
the number of Th17 cells, a subset that has recently been shown to
be involved in clearance of viral infections in vivo (Discussion).
Unlike CD8+ T cells, CD4+ T cells demonstrated no change in
the percentage of TNFa+ cells on deletion of NS1 or NS2 genes
(not shown).
Role of IFN-I in the NS1 mediated changes in the
activation and proliferation of CD8+ and CD4+ T cells
As noted (Introduction), we previously showed that the NS1
protein suppresses DC maturation, due in part to antagonism of
IFN-I production and signaling [28]. IFN-I also affects T cell
activation, polarization, and proliferation (Introduction, Discus-
sion). Therefore, the suppression of CD103+CD8+ T cells and
Th17 cells and enhancement of Th2 cells by NS1 might be
mediated by either or both of the two following mechanisms. First,
they might result from reduced production of IFN-I by DC,
resulting in reduced IFN-I signaling in T cells. Second, they might
result from a reduced level of DC maturation, thereby reducing
the ability of the DC to activate T cells.
As a first step in evaluating these possibilities, we investigated
the role of IFN-I production and signaling in co-culture
experiments in which IFN-I signaling was blocked with an
Figure 3. The NS1 protein suppresses activation and proliferation of CD103+ CD8+ T cells. A. Percentages of proliferating CD8+ T cells
positive for the indicated markers of activation, measured after co-culture with autologous DC that had been pre-infected with the DNS1 (shown in
red), DNS2 or DNS1/2 RSV (red) deletion mutants, as compared to cells from the same donors co-cultured with DC pre-infected with wt RSV (which
was assigned a value of 100%, dotted line). In addition, a duplicate of the wt RSV co-culture was prepared containing 133 IU each of exogenously
added IFNa2a and IFNb, similar to the amounts that are produced by DC infected with the DNS1 virus [28]. The markers of activation that were
analyzed are indicated on the top of each panel. A total of 9 donors were analyzed, indicated individually by symbols, and the horizontal bars
represent the mean values. In each panel, the mean amount of each subpopulation as a percentage of the total proliferating CD8+ T cells is shown
for wt RSV. Since only proliferating cells were analyzed, cells co-cultivated with mock-infected DC were not analyzed due to their near-absence of
proliferation (see Fig. 2A, B). For the DNS1 and DNS1/2 viruses, statistical significance compared to wt RSV is indicated by letter a, P,0.05. Statistical
significance is also indicated for wt RSV treated with IFNa2a and IFNb compared to un-treated wt RSV: a, P,0.05 (indicated for panel I only). B.
Examples of the primary flow cytometry data with cells from one representative donor; the percentage of each proliferated population is indicated.
doi:10.1371/journal.ppat.1001336.g003
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determine the effectiveness of the IFNAR2-specific antibody in
inhibiting IFN-I signaling, CD8+ (Fig. 6A) and CD4+ (Fig. 6B) T
cells were incubated for 2 h with a range of antibody
concentrations from 0.3 (Fig. 6A) or 0.03 (Fig. 6B) to 30 mg/ml
and then challenged with 100 IU/ml of IFNa2a. The T cells were
harvested at 3, 6, and 18 h post-IFN-challenge and the expression
of the IFN-I-inducible Mx1 (Fig. 6A and B) and ISG-56 (not
shown) genes were analyzed by quantitative RT-PCR (QRT-
PCR). This showed that the antibody effectively suppressed
induction of either gene even at a concentration that was one-
hundredth (Fig. 6A) or one-thousandth (Fig. 6B) of that used in
subsequent blockade experiments.
We then investigated the role of IFN-I in the effects on CD8+ T
cells in co-cultures. In preliminary experiments, we treated the DC
or T cells separately with IFNAR2-blocking antibody for various
times, washed away free antibody, and performed co-culture.
However, we found that we were unable to detect effects of the
antibody blockade on T cell activation (not shown). This perhaps
was not surprising, since new surface IFNAR2 molecules likely
appear during the long co-culture due to receptor recycling [52]
and proliferation. Therefore, we modified the protocol so that the
IFNAR2-blocking antibody would be present throughout the co-
culture incubation. One unavoidable limitation of this experimen-
tal design is that it would not allow us to distinguish directly
between effects on DC versus T cells. For these experiments, the
IFNAR2-blocking antibody, or an isotype control antibody, was
added at a 2-fold concentration (60 mg/ml) to CD8+ T cells, and
the cells were incubated for 1 h at 37uC, mixed with an equal
volume of autologous DC that had been pre-infected for 4 h with
wt RSV or DNS1/2 RSV or mock infected, and co-cultured with
the antibody present. In one of the four donors, the blockade
resulted in a substantial increase in the proliferation of CD8+ T
cells compared to the isotype control antibody, and in the other
donors, there was either no effect or a moderate reduction of
proliferation (Fig. 6C). Thus, a consistent effect was not observed,
and usually there was little effect. We next analyzed the effect of
IFNAR2 blockade on the proliferation of the CD103+CD8+ T
cells, the population most significantly up-regulated by deletion of
the NS1 protein, as previously shown in Fig. 3. Somewhat
surprisingly, this showed that the blockade increased the
percentage of CD103+ cells, an effect that occurred with either
virus (Fig. 6D). This is the opposite of the effect that would have
been expected if the increase in CD103+CD8+ T cells observed in
Fig. 3 for the NS1 and NS1/2 deletion viruses had been due to
increased IFN-I production and signaling.
Next, we evaluated the effects of exogenously added IFN-I on
CD8+ T cell activation and proliferation. Published studies have
variously demonstrated stimulatory or anti-proliferative effects of
IFN-I on CD8+ T cells (Introduction). We added increasing
amounts of an equal mixture of IFNa2a and IFNb at the
beginning of co-cultivation of wt RSV-infected DC with CD8+ T
cells. This resulted in inconsistent effects between the two donors,
with small, inconsistent increases or decreases in proliferation at
various doses. We next analyzed the CD103+CD8+ T cell
population and found that exogenous IFN-I reduced, rather than
increased, its percentage, although in cells from one donor this
effect was observed only at lower concentrations of IFN-I (Fig. 6F).
This is consistent with the antibody blockade results described
above in Fig. 6D. An inhibitory, rather than stimulatory, effect of
exogenous IFN-I on total CD103+ cells also was observed for most
of the donors in the experiments shown in Fig. 3A panel I, in
which a single dose of 133 IU/ml each of both IFNa2a and IFNb
was added (similar to the concentration produced by DC infected
with the DNS1 virus [28]), with the inhibition being statistically
significant (P,0.05). The finding that IFN-I and IFN-I signaling
suppress rather than stimulate the proliferation of CD103+CD8+
T cells indicates that the effects of NS1 deletion involve a
mechanism other than increased IFN-I production and signaling.
Next, we investigated the role of IFN-I in the effects on CD4+ T
cells in the co-culture system. We added IFNAR2-blocking
antibodies to CD4+ T cells 1 h prior to their co-cultivation with
DC that had been pre-infected with wt RSV or DNS1/2 RSV, as
described above for CD8+ T cells. With either virus, the blockade
of IFN-I signaling during co-culture resulted in an increased
proliferation of CD4+ T cells (Fig. 6G). However, the subpopu-
lations that were positive for IL-4 or IL-17 did not consistently
change with the IFNAR2 blockade (Fig. 6 H and I, respectively).
We note that, if increased IFN-I production and signaling indeed
had been responsible for the Th2 and Th17 effects observed in
Fig. 5, we would have expected to observe an increase in IL-4+ T
cells in Fig. 6H and a decrease in IL-17+ T cells in Fig. 6I, which
were not observed.
We then examined the effect of exogenously added IFN-I on
CD4+ T cell activation. Increasing amounts of a mixture of equal
quantities of IFNa2a and IFNb were added at the beginning of co-
Figure 4. Proliferation of CD4+ T cells during co-cultivation
with autologous DC pre-infected with wt RSV or its NS1/2
deletion mutants. A. Extent of CD4+ T cell proliferation in response
to DC infected with wt RSV or the NS1/2 deletion mutants, normalized
to results with wt RSV assigned the value of 100% (dotted line). In
addition, duplicate of wt RSV co-cultures were prepared containing
133 IU/ml each of exogenously added IFNa2a and IFNb. A total of 8
donors were analyzed, represented individually by symbols, and the
horizontal bars represent mean values. For wt RSV, the extent of CD4+
cell proliferation as a percentage of the total CD4+ population is
indicated. For the DNS1 and DNS1/2 viruses, statistical significance
compared to wt RSV is indicated by the letter c, P,0.001. B. Example of
primary flow cytometry data for cells from one representative donor;
the percentage of each proliferated population is indicated.
doi:10.1371/journal.ppat.1001336.g004
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earlier with CD8+ T cells (above). Addition of the IFN-I cocktail
resulted in a dose-dependent reduction in the proliferation of
CD4+ T cells (Fig. 6J), which is consistent with our previously
published study [15]. However, analysis of individual populations
of CD4+ T cells demonstrated a lack of consistent effect on IL-4+
cells (Fig. 6K), and a modest decrease in IL-17+ cells that was not
dose-dependent (Fig. 6L). We note that, if increased IFN-I
production and signaling had been responsible for the Th2 and
Th17 effects observed in Fig. 5, we would have expected to
observe a decrease in IL-4+ T cells in Fig. 6K and an increase in
IL-17+ T cells in Fig. 6L, which were not observed.
In summary, IFN-I production and signaling in the co-cultures
had effects on proliferation of the total population of CD4+ T cells.
However, the three major effects associated with the presence of
the RSV NS1 protein, namely the reduced proliferation and
activation of CD103+CD8+ T cells, the reduced activation and
proliferation of Th17 cells, and the skew in the Th1/Th2 balance
Figure 5. The NS1 protein affects the polarization of CD4+ T cells. A, B. The NS1 protein shifts the phenotype of CD4+ T cells towards Th2. A.
Percentages of proliferating CD4+ T cells positive for the indicated markers of activation after co-culture with autologous DC that had been pre-
infected with the DNS1 (red), DNS2, and DNS1/2 (red) deletion mutants, as compared to the cells from the same donors co-cultivated with DC pre-
infected with wt RSV (assigned a value of 100%, doted line). B. Examples of primary flow cytometry data using cells from one representative donor,
with the percentage of each population indicated. C, D. The NS1 protein reduces activation and proliferation of Th17 cells. C. Percentages of
proliferating CD4+ T cells positive for the indicated markers of activation after co-culture with autologous DC that had been pre-infected with the
indicated virus, as compared to wt RSV in cells from the same donor as 100%. D. Examples of primary flow cytometry data using cells from one
representative donor, with the percentage of each population indicated. In A-D, cells co-cultivated with mock-infected DC were not analyzed due to
the near-absence of proliferation (see Fig. 4). In addition, duplicate of wt RSV co-cultures were prepared containing 133 IU/ml each of exogenously
added IFNa2a and IFNb. In A and C, the markers of activation that were analyzed are indicated on the top of each panel. A total of 8 donors were
analyzed, represented by individual symbols, and the horizontal bars indicate mean values. In each panel, the amount of each subpopulation as a
percentage of the total proliferating CD4+ T cells is shown for wt RSV. For the DNS1 and DNS1/2 viruses, the statistical significance of the difference
to wt RSV is indicated in blue as follows: a, P,0.05; b, P,0.01, c, P,0.001.
doi:10.1371/journal.ppat.1001336.g005
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PLoS Pathogens | www.plospathogens.org 7 April 2011 | Volume 7 | Issue 4 | e1001336Figure 6. Role of IFN-I in the proliferation of CD8+ and CD4+ T cells. A, B. Effectiveness of an IFNAR2-blocking antibody in inhibiting IFN-I
signaling. CD8+ (A) and CD4+ (B) T cells from 3 donors were incubated with the indicated concentrations of the IFNAR2 blocking antibody for 2 h,
followed by stimulation with 100 IU/ml of IFNa2a. Cells were harvested at 3, 6, and 18 h post-IFN-I treatment, MX1 expression was determined by
QRT-PCR and reported as relative expression normalized to cells exposed to IFN-I without antibody. C, D. Effect of IFNAR2-blocking antibodies on
proliferation of total CD8+ cells (C) and CD103+CD8+ cells (D). The IFNAR2-blocking antibodies or isotype control antibodies were added to CD8+ T
cells 1 h prior to their mixing with DC pre-infected with wt RSV or DNS1/2 RSV, and the antibodies remained during the co-culture. The level of CD8+
T cell proliferation was normalized to that for cells from the same donor incubated with isotype control antibodies, which was assigned the value of
100% (dotted line). Four donors were analyzed. The statistical significance of the difference between co-culture treated with IFNAR2-blocking
antibody compared to its isotype control is indicated by the letter a, P,0.05. E, F. Effect of exogenously added IFN-I on the proliferation of total
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signaling during co-culture.
RSV NS1/2 proteins suppress multiple factors of DC
maturation that are only partly regulated by secreted
IFN-I
We also investigated the effects of IFN production and signaling
on DC. We treated DC from four donors with the IFNAR2
blocking or isotype control antibody for 2 h and then infected
them with wt RSV or DNS1/2 RSV followed by 48 h incubation
in the presence of the blocking antibody. The cells were harvested,
total RNA was purified, and mRNAs encoding 49 proteins
relevant to DC maturation and function were analyzed by QRT-
PCR using a microfluidic gene card format. The results are
displayed as a heat map (Fig. 7A) and in some cases in linear plots
(Fig. 7B).
We found that deletion of the NS1 and NS2 genes resulted in a
dramatic transcriptional up-regulation in a number of mRNAs
including ones encoding type I and type III IFNs and other
cytokines, molecules involved in antigen presentation and
signaling, co-stimulatory factors, and pattern recognition recep-
tors. The IFNAR2-blocking antibody strongly reduced the
expression of the IFN-I-stimulated genes CXCL9, CXCL10,
and RIG-I (Fig. 6A, B), suggesting that the blockade of IFN-I
signaling was effective. The strong IFNAR2 blockade did not
reduce the expression of IFNa mRNA (Fig. 6A); also, ELISA
analysis of secreted IFNa in the medium demonstrated a 14-fold
greater mean concentration for DNS1/2 RSV compared to wt
RSV (data not shown). This observed expression of IFNa in the
face of the IFNAR2 blockade presumably arises by a mechanism
that is not dependent on signaling from the IFNAR, such as
through activation of IRF7 or IRF5 that are constitutively
expressed in human monocyte-derived DC [53]. We found that
the IFNAR2 blockade resulted in a partial transcriptional down-
regulation of DC maturation markers including CD38, CD40 and
CD80 (Fig. 6A, B), in a dose-dependant manner (data not shown).
This is consistent with our previous study, which showed that only
part of the maturation of DC in response to wt RSV or the DNS
mutants appeared to be IFN-I-dependent [28]. These results
suggest that NS1/2 suppress multiple factors of DC maturation
and that this suppression is only partially regulated by secreted
IFN-I. For example, we note that the levels of IL-12b and IL-23a
mRNA which enhance Th1 and Th17 responses, respectively,
were increased 57-759-fold and 49-134-fold, respectively, in DC
infected with the DNS1/2 virus compared to wt RSV (Fig. 7A, B).
The level of expression of each was increased rather than
decreased by the IFNAR2 blockade: thus, the expression of IL-
12b and IL-23a was suppressed by NS1, but not due to suppressed
IFN-I production and signaling.
The NS1 protein suppresses the levels of IFNc in co-
cultures of RSV-infected DC and T cells
Analysis of cytokine expression by flow cytometry reliably
determines the percentage of cells that are positive for expression,
but since in vitro stimulation can induce high levels of expression,
the MFI does not necessarily provide an accurate comparison of
the level of expression. We therefore also analyzed selected
cytokines by ELISA. We performed co-culture of wt and mutant
RSV-infected DC with autologous CD8+ or CD4+ T cells, and
after 7 days of incubation, analyzed the co-culture media
supernatants by ELISA for IFNc and TNFa (CD8+ T cell co-
cultures), or IFNc, IL-2, IL-4, IL-12 and IL-17 (CD4+ T cell co-
cultures). We found that for both CD8+ and CD4+ T cells from
most of the donors, the deletion of the NS1 gene was associated
with increases in the concentration of secreted IFNc (mean
increases of 70% and 31%, respectively), whereas deletion of both
the NS1 and NS2 genes resulted in somewhat lesser increases
(Fig. 8). The other cytokines analyzed by ELISA were either not
detected or were detected at very low levels (not shown), reflecting
a limitation of this method. The addition of exogenous IFN-I at
various concentrations (data not shown) or at a single dose
(133 IU/ml of IFNa2a and IFNb each, Fig. 8) during the co-
cultures of wt RSV-infected DC with T cells did not significantly
affect IFNc production (Fig. 8 and data not shown). Thus, the
presence of the NS1 gene changed the cytokine microenvironment
towards reduced secretion of IFNc, and this effect was not altered
by added IFN-I.
Discussion
We demonstrated, using primary human immune cells, that the
RSV NS1 protein induces quantitative and qualitative deficiencies
in adaptive immunity. In particular, the NS1 protein (i) suppresses
the CD103+ CD8+ T cell response, (ii) promotes a Th2 response,
and (iii) suppresses the Th17 response (Fig. 9). Thus, NS1
suppresses two mechanisms that play a protective role during RSV
infection (CD103+ CD8+ T cells and Th17 cells) and stimulates a
mechanism contributing to enhanced disease (Th2 cells). A role for
CD8+ T cells in restricting and clearing RSV infection is well
established [54,55]. Following infection with RSV or influenza
virus, virus-specific CD8+ CTL accumulate in lungs at much
greater concentration than in the peripheral blood [30]. Mucosal
CD8+CTL, but not their peripheral blood counterparts with the
same antigenic specificity, are highly positive for CD103 and have
the effector memory phenotype [56]. The presence of CD103 on
the surface of lung CD8+ CTL is important for respiratory
epithelial cell-specific tropism and cytotoxicity due to expression of
E-cadherin by epithelial cells, which specifically binds CD103
[34,57]. A study with human lung tumor tissues and tumor-specific
CD8+ CTL demonstrated that the interaction of CD103 with E-
CD8+ cells (E) and CD103+CD8+ T cells (F). IFNa2a and IFNb, each at the indicated concentration (IU/ml), were added at the beginning of co-culture of
CD8+ T cells and DC that had been pre-infected with wt RSV. The amount of CD8+ T cell proliferation in each IFN-I-treated culture was normalized
relative to untreated cells, which were given the value of 100% (dotted line). Two donors were analyzed. In panels E and F, the amount of
proliferating CD8+ (1.5%) or CD103+CD8+ (7.5%) T cells, respectively, as a percentage of the total CD8+ T cells, is shown for wt RSV lacking
exogenous IFN-I treatment. G, H, I. Effect of IFNAR2 blockade on the proliferation of total CD4+ T cells (G) or the indicated subpopulation (H and I);
representative data from 2 donors. CD4+ T cells were treated with IFNAR2-blocking antibodies or isotype control antibodies for 1 h prior to their
mixing with DC pre-infected with wt RSV or DNS1/2 RSV, with the antibodies present during the co-culture. The levels of proliferated CD4+ T cells in
G, H and I are normalized to that for cells from the same donor treated with isotype control antibodies (100%, dotted line). J, K, L. Effect of
exogenously added IFN-I on proliferation of total CD4+ T cells (J) or the indicated subpopulation (K and L); representative data from 2 donors. IFNa2a
and IFNb, each at the indicated concentration (IU/ml), were added at the beginning of co-culture of CD4+ T cells and DC that had been pre-infected
with wt RSV. The amount of CD4+ T cell proliferation in each IFN-I-treated culture was normalized relative to untreated cells, which were given the
value of 100% (dotted line). In panels J, K and L, the mean number of proliferating CD4+ cells as percentages of the total CD4+ T cells (77%, 9.3% and
0.7%, respectively) are shown for wt RSV lacking exogenous IFNa2a and IFNb.
doi:10.1371/journal.ppat.1001336.g006
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polarization and exocytosis [34]. Similarly, it was found that, in
human bronchoalveolar lavages, a much greater fraction of both
CD4+ and CD8+ T cells expresses CD103, as compared to that in
the peripheral blood, and that the CD103 molecule is required for
effective lysis of E-cadherin-expressing target cells [35,57].
Figure 7. Effect of NS1/2 deletion and IFNAR2 blockade on the transcriptional induction of DC genes. A. QRT-PCR analysis of RNA
isolated from DC infected with wt RSV or DNS1/2 RSV and treated with IFNAR2 antibody, or an isotype control, or treated with LPS or mock. Total
cellular RNA was harvested 48 h post-infection and analyzed by QRT-PCR for the indicated mRNAs using a microfluidic gene card. The expression fold
change for each treatment was calculated relative to the calibrator, i.e., DC infected with wt RSV without the antibody treatment, converted to log2
and used for hierarchical clustering to obtain a heat map. The data from four individual donors are shown (indicated by numerals 1, 2, 3, and 4 on top
of the heat map). Each row represents expression status of one gene with the gene name indicated on the right of each row. Genes were divided into
four major functional categories indicated on the right of the heat map. Each functional group was clustered separately with the color bar shown on
the left of the heat map representing the color range and the corresponding expression fold change indicated by it (red, up-regulated; green, down-
regulated; black, no change; grey, mRNA not detected). B. Linear plots of the changes in the concentrations of mRNA for CXCL9, CXCL10, RIG-I, CD38,
CD40, CD80, IL-12b, and IL-23a, from the experiment in part A. The 4 donors are indicated individually by symbols, and the horizontal bars represent
the mean values. The y-axis shows expression fold change relative to wt RSV not treated with antibody. The statistical significance of difference was
determined by repeated measures ANOVA with Tukey’s multiple comparison post test and the significance of the difference between DNS1/2 and wt
RSV or between DNS1/2 and DNS1/2 pretreated with IFNAR2 antibody is indicated in blue as b, P,0.01 and c, P,0.001.
doi:10.1371/journal.ppat.1001336.g007
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lung tumors by a CCR5-dependent mechanism [37]. Thus,
CD103 is a molecule expressed at high levels by mucosal and, in
particular, pulmonary CTL, and is associated with their mucosal
homing, cytotoxicity against respiratory tract epithelial cells, and
their subsequent retention as effector memory T cells. Accumu-
lating evidence thus indicates an important role for CD103 in
pulmonary CTL-mediated lysis of virus-infected cells of the
respiratory epithelium and thus protection against respiratory
viruses. Therefore, the suppression of activation and proliferation
of CD103+CD8+ CTL by the RSV NS1 protein demonstrated in
this study identifies a new mechanism by which the virus
suppresses an important protective component of the adaptive
immune response.
Th17 cells were initially found to have a pro-inflammatory
effect and to be involved in autoimmune diseases [58]. Subsequent
studies elucidated their role in innate and adaptive immune
response against pathogens. One of the major functions of IL-17 is
the recruitment of neutrophils [59]. Infection of bronchial
epithelial cells with rhinovirus, a human respiratory pathogen,
demonstrated that the IL-17-mediated recruitment of neutrophils
is related to its ability to induce IL-8, which is a neutrophil
chemoattractant [60]. Neutrophils play an essential role in
antibody-mediated neutralization of influenza virus in vivo [61]
and play a critical role in the activation of natural killer cells [62].
Using Listeria monocytogenes, it was found that Th17 cells are much
more strongly induced by the respiratory route of infection than by
the intravenous route [63]. It has only recently been found that
Th17 cells play a role in protection against viruses. IL-17
produced by Th17 cells facilitates clearance of vaccinia virus
infection in mice, most likely by the attraction of neutrophils [64].
Th17 cells have also been shown to protect mice from a lethal dose
of influenza virus by a mechanism independent of IFNc, T cell
helper function, or perforin-mediated cytotoxicity, and which
possibly involves reduction in the severity of lung damage and/or
effect on the rate of lung repair [65]. Th17/Th1 cells exhibit
functional properties similar to those of Th17 cells [51]. Thus, the
suppression of proliferation of IL-17+ CD4+T cells (Th17 cells) or
IL-17+IFNc+ CD4+ T cells (Th17/Th1 cells) by the RSV NS1
protein found in this study suggests yet another novel mechanism
the virus uses to counteract the anti-viral effects of both the
adaptive (the Th17 and Th17/Th1 cells) and the innate (secreted
IFNc) components of the immune system.
Severe RSV disease likely is influenced by a variety of factors
whose individual importance varies in the heterogeneous human
population and likely also with age. One proposed scenario
involves a skewing of the Th1/Th2 balance of the virus-specific
response towards Th2, which includes down-regulation of the
CD8+ CTL response and a B cell switch from synthesis of virus-
specific protective IgA and IgG to non-protective IgE (reviewed in
[16,66]). A Th2 bias also has been implicated for a formalin-
inactivated RSV vaccine that was evaluated in infants and
children in the 1960s and resulted in a greatly increased frequency
and severity of disease upon subsequent natural RSV infection
[16,66]. Moreover, a number of studies over the past decade have
suggested that severe RSV disease may sometimes be linked to
various genetic factors, including those controlling the expression
of or response to Th2 cytokines [67]. In particular, polymorphisms
leading to an increased activity of IL-4 and IL-13 appeared to be
overrepresented in infants and children with severe RSV disease
[68,69,70,71]. In the present study, NS1 expressed by wt RSV not
only increased the percentage of CD4+ T cells positive for IL-4
(Fig. 5A,B), but also enhanced proliferation of these cells by
antagonizing the anti-proliferative effect of IFN-I (Fig. 4). NS1 also
depressed the concentration of IFNc in DC-T cell co-cultures
(Fig. 8), thus favoring the Th2 response. These data suggest that
the NS1 protein contributes to skewing of the Th1/Th2 balance
towards Th2 during the priming of naive T cells or stimulation of
memory T cells. The idea that NS1 can skew the T cell response
towards Th2 was indicated in previous work. Specifically, when
RSV-infected human DC were treated with small interfering RNA
targeting the NS1 gene and co-cultivated with heterologous RSV-
naı ¨ve cord blood CD4+ T cells, the percentage of IFNc+ cells
increased, and that of IL-4+ cells decreased [72]. However, what is
surprising in the present study is that these effects do not appear to
be dependent on IFN-I production and signaling, as described
below.
Since the RSV NS genes are IFN-I antagonists, the most
obvious explanation for the effects of NS1 deletion observed in the
present study would be that they are mediated by increased IFN-I
production and signaling, which are known to affect DC
maturation and T cell activation, polarization and proliferation.
For example, as noted, NS1 suppresses DC maturation, due in
part to inhibition of IFN-I production and signaling [28]. IFN-I
has been reported to have stimulatory or inhibitory effects on
CD8+ T cell proliferation, depending on the situation (Introduc-
tion). Type I and type III IFN have been reported to suppress
activation and proliferation of CD4+ T cells during co-culture
with RSV-infected DC [15]. IFN-I has been shown to promote a
Th1 response by increasing the frequency of human IFNc-
secreting CD4+ Th cells and antagonizing the suppressive effect of
IL-4 on IFNc production [73,74]. In the present study, one effect
indeed did appear to be mediated directly by changes in IFN-I
production and IFN-I signaling: specifically, proliferation of total
CD4+ T cells was inhibited by IFN-I. However, the other
observed effects, namely the suppression of CD103+CD8+ T cells
Figure 8. Concentrations of IFNc in the DC-T cell co-cultures.
The CD8+ (A) and CD4+ (B) T cells were co-cultured with DC pre-
infected with wt RSV, DNS1, DNS2 or DNS1/2 RSV, and IFNc
concentrations were determined by ELISA. In addition, duplicate of
wt RSV co-cultures were prepared containing 133 IU/ml each of
exogenously added IFNa2a and IFNb. The data are normalized to that
for wt RSV, which was assigned the value of 100% (dotted line). 9 and 3
donors were analyzed for A and B, respectively, represented by symbols
with the means indicated by horizontal bars. In each panel, the mean
concentration of IFNc in pg/ml is indicated for wt RSV. In part A, a
significant difference to wt RSV is indicated by the letter b, P,0.01.
doi:10.1371/journal.ppat.1001336.g008
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appear to be directly mediated by changes in IFN-I production
and signaling (Fig. 9). This was suggested by several observations.
For example, while both NS1 and NS2, individually and in
combination, antagonize IFN-I production and signaling in
epithelial cells (Introduction), the effects in the present study were
seen only in response to deletion of NS1 and not the NS2 protein.
The inclusion of IFNAR2-blocking antibody in the co-cultures
provided evidence that the NS1-specific effects on CD103+CD8+
cells, Th17 cells, and Th2 cells were not due to changes in IFN-I
production or signaling. This also was indicated in the experiments
in which exogenous IFN-I was added to the co-cultures.
An alternative possibility is that these NS1-mediated effects
involve suppression of pathways that do not depend on IFN-I
production and signaling. As noted, maturation of DCs in
response to RSV is partly independent of IFN-I production and
signaling [28]. Similarly, Lopez et al. previously demonstrated that
the maturation of DC in response to negative strand RNA viruses
involves intracellular IFN-I induction pathways, including activa-
tion of nuclear factor-kB, but not the released IFN-I or subsequent
IFN-I signaling [75]. In the present study, infection of DC with the
DNS1/2 mutant induced a strong up-regulation in the transcrip-
tion of multiple genes involved in DC maturation and T cell
activation (Fig. 7A, B). Much of this up-regulation was suppressed
by wt RSV. The role of IFN-I in this up-regulation was assessed
with IFNAR2-blocking antibody. The blockade strongly reduced
expression of CXCL9, CXCL10 and RIG-I, which are known to
be induced mainly by IFN-I [76,77,78]. In contrast, the blockade
only partly reduced the up-regulation of several maturation-
related markers including CD38, CD40, and CD80 among others.
Thus, we suggest that the effects on the T cells observed in the
present study result from NS1-mediated suppression of signaling
pathways leading to DC maturation, which likely include signaling
pathways leading to induction of IFN-I, but are independent of
secreted IFN-I and IFN-I signaling. IL-12 and IL-23 also may be
involved. IL-12 and IL-23 are involved in polarization of T cell
response toward Th1 [79] and maintenance of the Th17 cell
population [80], respectively. The expression of each by RSV-
infected DC was increased by deletion of NS1/2. This did not
appear to be a result of increased IFN-I production and signaling
because the IFNAR2 blockade increased rather than decreased
expression, indicative of suppression rather than stimulation by
IFN-I (Fig. 7A, B). Suppression of IL-12 expression by IFN-I also
has previously been reported in humans and mice [81,82]. NS1
also reduced secretion of IFNc by both CD8+ and CD4+ T cells.
IFNc promotes the differentiation of Th cells to Th1 and
suppresses their development to Th2 phenotype, and IFNc
secreted by CD8+ T cells prevents Th2-driven pathology during
RSV infections [83,84]. Thus, suppression of IFNc secretion by
CD4+ T cells, which was not reversed by exogenous IFN-I, may
be involved in the Th2-promoting effect of the NS1 protein
demonstrated in this study.
In conclusion, the data presented in this study suggest that the
RSV NS1 protein has quantitative and qualitative effects on the
adaptive immune response, thus promoting infection and disease.
The experimental system used in this study involved human
primary cells from adult donors and thus represents a model of the
immune system of RSV-immune children and adults for investiga-
tion of the effects of immunomodulating RSV proteins on the virus-
specific memory T cells. However, the pattern of immune response
to RSV depends on age and is biased towards Th2 in neonates [85].
Therefore, it is possible that, in RSV-naı ¨ve individuals, the three
major effects of the NS1 protein, especially that of enhanced Th2
activity, might be even more pronounced than in adults.
Figure 9. The effects of RSV NS1 protein on T cells. A model of the effects of the RSV NS1 protein on maturation of DC, activation and
proliferation of three populations of T cells (CD103+CD8+, IL-4+CD4+ and IL17+CD4+), role of IFN-I, and the effect of NS1-mediated regulation of
these cell populations on the host adaptive immunity and RSV disease.
doi:10.1371/journal.ppat.1001336.g009
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Virus propagation and purification
Virus growth and purification were performed as described
previously [28,86]. Briefly, Vero cells were maintained in Opti-
MEM I mefdium (Invitrogen, Carlsbad, CA) supplemented with
5% heat-inactivated fetal bovine serum (FBS) (HyClone, Logan,
UT), 2 mM L-glutamine, 100 IU/ml penicillin and 100 mg/ml
streptomycin sulfate (Invitrogen). Recombinant wild type (wt) RSV
strain A2 and RSV A2 deletion mutants lacking NS1 (DNS1), NS2
(DNS2) or both NS1 and NS2 (DNS1/2) genes, all expressing
enhanced green fluorescent protein to monitor DC infection,
described previously [28], were propagated in Vero cells. Virus-
infected Vero cell supernatants were harvested and viruses were
purified by sucrose gradient centrifugation. In order to eliminate
sucrose from purified viruses, virus bands were diluted with
Advanced RPMI 1640 medium with 2 mM L-glutamine (Invitro-
gen), and the viruses were pelleted at 8,000 x g for 2 h at 4uC,
followed by re-suspension in the same medium. Aliquots of the
viruses were stored at 280uC and titers were determined by
plaque assay as previously described [87].
Preparation of DC and T lymphocytes
Elutriated monocytes obtained from healthy adult donors
according to an approved clinical protocol were provided by the
NIH blood bank and were differentiated into monocyte-derived
DC cultures as described previously [28]. Briefly, CD14+
monocytes were purified by positive selection using anti-CD14
monoclonal antibody-conjugated magnetic microbeads and an
Automacs separator (Miltenyi Biotech, Auburn, CA), and were
cultured with granulocyte-macrophage colony-stimulating factor
(GM-CSF) and IL-4. Cultures were incubated at 37uC for 7 days
during which time the cells developed phenotypic features of
immature DC (CD1a
+ CD14
low CD38
low CD11c
high) [88].
Autologous elutriated lymphocytes from the same donors were
also provided by the NIH blood bank and were purified by density
centrifugation in Ficoll-Hypaque (Cellgro-Mediatech, Manassas,
VA), harvested and washed in Advanced RPMI 1640 medium
(Invitrogen) supplemented with 10% FBS (HyClone) and 2 mM L-
glutamine (Invitrogen). Lymphocytes were cryopreserved in
Advanced RPMI 1640 medium containing 10% FBS (HyClone),
2 mM L-glutamine (Invitrogen), 10% dimethyl sulfoxide (DMSO)
(Cellgro-Mediatech) at a cell density of 4610
7 cell/ml. Before use,
the lymphocytes were thawed and cultured overnight in Advanced
RPMI 1640 medium supplemented with 10% human serum
(Gemini Bio-products, West Sacramento, CA), 2 mM L-gluta-
mine, 200 IU/ml penicillin, and 200 mg/ml streptomycin sulfate
(Invitrogen). The next day, CD8+ T cells were purified from
lymphocytes by negative selection with an Automacs separator
using a primary cocktail of antibodies conjugated to biotin and
secondary anti-biotin antibody conjugated to magnetic microbe-
ads to deplete non-CD8+ T cells, including CD4+ T cells, c/d T
cells, B cells, NK cells, DC, monocytes, granulocytes, and
erythroid cells. The cells were analyzed for purity by staining
with anti-CD8 phycoerythrin (PE)-conjugated antibodies (BD
Biosciences, San Jose, CA) and flow cytometry. CD4+ T cells were
isolated from lymphocytes by positive selection with an Automacs
using anti-CD4 monoclonal antibody-coated magnetic microbeads
(Fig. 1A). The purity of the cells was assessed by staining with anti-
CD4 fluorescein isothiocyanate (FITC)-conjugated antibodies (BD
Biosciences) and flow cytometry. The purity of CD8+ and CD4+
T cells was 85–95% and .98%, respectively. Purified CD8+ and
CD4+ T cells were labeled with CFSE (Invitrogen) as per the
manufacturer’s instructions, in order to monitor cell proliferation
as assessed by reduction in the CFSE fluorescence intensity due to
cell divisions.
Infection of DC and co-culture with T cells
On day 7 of culture, when monocytes had differentiated into
DC, they were harvested and labeled either with CellVue
Lavender (Molecular Technologies, West Chester, PA) or
7-hydroxy-9H-(1,3-dichloro-9,9-dimethylacridin-2-one) (DDAO)
(Invitrogen) fluorescent tracers, as per manufacturer’s instructions,
for co-culture with CD8+ and CD4+ T cells, respectively (Fig. 1A).
Following labeling, DC were inoculated with wt RSV, DNS1,
DNS2 or DNS1/2 RSV at MOI of 2 PFU/cell, mock treated or
treated with Staphylococcal Enterotoxin B (SEB) (Sigma-Aldrich,
St. Louis, MO) at 1 mg/ml. After 4 h of incubation, DC were
washed to remove virus inoculum and were co-cultured with
purified autologous CFSE-labeled CD8+ or CD4+ T cells at a
DC: lymphocyte ratio of 1:10 (2610
5 DC: 2610
6 lymphocytes) in
2 ml of Advanced RPMI 1640 medium (Invitrogen) containing
10% human serum (Gemini Bio-Products), 2 mM L-glutamine,
200 IU/ml penicillin, and 200 mg/ml streptomycin sulfate (all
Invitrogen) in 12-well plates. Co-cultures were incubated at 37uC
for 7 days. This is based on our previous finding that proliferation
was minimal by day 4 and requires 7 days to be substantial [89].
On day 5, 1 ml of fresh medium was added to the 2 ml of pre-
existing medium of each co-culture. Since the deletion of NS1
protein significantly increases the production of IFN-I from
infected DC, which may in turn be responsible for the T cell
phenotypes observed in our experiments, a control was included
where exogenous IFNa2a and IFNb (PBL Interferon Source,
Piscataway, NJ) were added at 133 IU/ml each to co-culture of
DC pre-infected with wt RSV with CD4+ as well as CD8+ T cells
to monitor such effects. The quantity of IFN-I added to this
control was based on our previous studies [28] and represents the
average amount produced by human monocyte-derived DC on
infection with the viruses lacking NS1.
For IFN-I receptor blocking experiments, mouse monoclonal
anti-human IFNAR2-neutralizing antibody (PBL Interferon
Source) or its isotype control antibody (R&D Systems, Minneapolis,
MN) was added to the purified CD8+ or CD4+ T cells at a final
concentration of 60 mg/ml and incubated for 1 h at 37uC. We
chose to use an IFNAR2-blocking antibody because the antiviral
activity of IFN-I correlates well with signaling through IFNAR2
rather than IFNAR1 [90]. This mixture was then combined with
autologous DC that had been pre-infected with wt RSV or DNS1/2
RSV at MOI of 2 PFU/cell or mock infected as described, resulting
in final antibody concentration of 30 mg/ml. The co-cultures were
incubated at 37uC for 7 days. In another format, the antibody was
added to DC for 2 h, followed by infection and additional
incubation for 48 h, wash and co-cultivation with T cells as above.
To determine the effect of IFN-I, an equal mixture of IFNa2a and
IFNb (PBL Interferon Source) was added exogenously to a final
concentration of 25, 50, 100, 133, 200, 400, 800, or 1,600 IU/ml
each to the co-cultures of DC pre-infected with wt RSV and CD8+
orCD4+ T cells.Theco-cultureswere incubatedat37uCfor7 days.
Staining of CD8+ and CD4+ T cells
After 7-days of co-culture, medium supernatants were collected
for cytokine assay. The co-cultures were then prepared for
intracellular cytokine staining by stimulation with phorbol-12-
myristate-13-acetate (PMA) (Sigma Aldrich, St. Louis, MO) at
20 ng/ml and ionomycin (EMD Chemicals, Gibbstown, NJ) at
1 mM in the presence of brefeldin A (Sigma Aldrich) at 10 mg/ml,
and were incubated at 37uC for 6 h; 5 min before the harvest,
DNase I (Calbiochem, Gibbstown, NJ) was added at 150 mg/ml.
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Dead Cell Stain (Invitrogen) to discriminate dead cells by flow
cytometry. CD8+ T cells were also stained with PE-labeled anti-
CD103 antibodies (BD Biosciences), peridinin chlorophyll protein
(PerCP-Cy5.5)-labeled anti-CD107a antibodies (Biolegend, San
Diego, CA), and pacific orange-labeled anti-CD8 antibodies
(Invitrogen). After surface staining, cells were fixed and permea-
bilized using fixation/permeabilization kit (BD Biosciences) as per
the manufacturer’s instructions. Cells were then blocked and
permeabilized by overnight incubation in phosphate buffered
saline containing 0.1% saponin and 5% non-fat dry milk. CD8+ T
cells were then stained for intracellular cytokines and cell markers
with allophycocyanin-Alexa Fluor 750 (APC-Cy7)-labeled anti-
IFNc (Invitrogen), PE-Cy7-labeled anti- TNFa (BD Biosciences),
APC-labeled anti-IL-2 (BD Biosciences), and PE Texas Red-
labeled anti-CD3 antibodies (Beckman Coulter, Brea, CA). CD4+
T cells were stained for intracellular cytokines with APC-Cy7-
labeled anti-IFNc (Invitrogen), PE-labeled anti-IL-4 (BD Biosci-
ences), PerCP-Cy5.5-labeled anti-IL-17A (eBioscience, San Diego,
CA), PE-Cy7-labeled anti- TNFa (BD Biosciences), and Alexa-
Fluor 680-labeled anti-IL-2 antibodies (Biolegend). The stained
cells were suspended in staining buffer [phosphate buffered saline,
1% FBS (HyClone)] for flow cytometry analysis.
Multi-color flow cytometry
Ten-parameter and 9-parameter flow cytometric analysis was
performed for CD8+ and CD4+ T cells, respectively, on a Becton
Dickinson LSR II flow cytometer (BD Biosciences). Data
compensation was performed using mouse and rat CompBeads
compensation beads (BD Biosciences) stained with individual
antibodies used in the multicolor analysis. Data acquired from the
T cells stained only with CFSE and that from DC stained only
with CellVue Lavender dye or DDAO were used for compensa-
tions involving these fluorochromes. The data were analyzed with
FlowJo software version 8.8.6 (Tree Star, Ashland, OR). The data
acquired from stained compensation beads and cells were used for
automatic compensation using the FlowJo Compensation Wizard.
In order to determine the accuracy of compensation between
overlapping spectra and to define the positive cells, fluorescence-
minus-one (FMO) staining controls were included. The FMO
controls included staining of CD4+ T cells, derived from co-
cultures with wt RSV-infected DC, with fluorochrome-conjugated
antibodies for all cytokines omitting one antibody conjugate per
control. The gating strategy followed to obtain proliferated CD8+
or CD4+ T cells for analyses is shown in Fig. 1B. Briefly, the
compensated data were gated at UV Live/Dead stain versus
CellVue Lavender dye or DDAO to eliminate dead T cells and all
DC, and to obtain live T cells. Live T cells were then gated at UV
Live/Dead dye versus CD3 to obtain live CD3+ T cells, which
were then gated at forward scatter area versus forward scatter
height to eliminate cell doublets and clusters and to identify single
cells for analyses. Single cells thus identified were again gated at
forward scatter area versus side scatter area to exclude any debris
and determine cell size and granularity. These cells were then
finally gated at CD3 versus CFSE to identify proliferated CD3+ T
cells as assessed by reduction in fluorescence intensity of CFSE as a
result of cell divisions. For CD8+ T cells, an additional gate was
drawn after gate 2 at CD3 versus CD8 to identify CD3+ CD8+ T
cells. The proliferated cells thus obtained were further gated for
individual cytokines and activation markers including CD103,
CD107a, IFNc, TNFa and IL-2 for CD8+ T cells, and IFNc, IL-
4, IL-17, TNFa and IL-2 for CD4+ T cells. The FMO controls
demonstrated that cells stained with all but one cytokine antibody
were indeed negative for that cytokine (Fig. S2). This suggests that
the electronic compensations applied to the data were accurate,
and that the cells found positive for a particular cytokine were
indeed a result of specific staining with the corresponding antibody
conjugate and were not false positives due to fluorescence
contribution from the overlapping spectra. Proliferated T cells
gated positive for individual cytokines were analyzed by Boolean
gating to obtain frequencies for 32 possible cytokine combinations
both positive and negative for individual cytokines using FlowJo
software. The identified cell populations were further analyzed
using Pestle and Spice software (version 4.2.3; Mario Roederer
and Joshua Nozzi, Vaccine Research Center and Bioinformatics
and Scientific IT Program, NIAID, NIH, Bethesda, MD). Data
obtained by Boolean gating were normalized to wt RSV and
plotted for graphical representation using Prism 5 software
(GraphPad software Inc., La Jolla, CA).
Analysis of mRNA isolated from RSV-infected DC and T
cells by QRT-PCR
DC were treated with the IFNAR2 blocking antibody or its
isotype control for 2 h and then infected with wt RSV or DNS1/2
RSV, followed by 48 h-long incubation and analysis of maturation
markers by QRT-PCR. Total RNA was extracted from DC using
RNeasy kit (Qiagen, Valencia, CA) and used to synthesize cDNA
using Superscript III reverse transcriptase kit (Invitrogen) as per
manufacturer’s protocol. The cDNA thus obtained was used to
analyze 49 genes (the full gene names and the NCBI gene
reference numbers are provided in Table S1) in triplicate by
QRT-PCR on a TaqMan micro fluidic gene card (Applied
Biosystems, Foster City, CA) using TaqMan universal PCR master
mix (Applied Biosystems). The 18S ribosomal RNA was included
on the gene card in triplicate and used as an endogenous control
for analysis. PCR was run on 7900HT fast real-time PCR system
(Applied Biosystems). The threshold cycle (Ct) values obtained for
DC infected with wt RSV without any antibody treatment were
used as the calibrator for calculating the fold change in gene
expression for the rest of the treatments. The entire experiment
was performed four times using DC prepared from four individual
donors. The expression fold change values were converted to log2
and analyzed with Genesis software version 5 (Alexander Sturn,
Institute for Genomics and Bioinformatics, Graz University of
Technology, Petersgasse, Austria) to perform the hierarchical
clustering of data and generate a heat map. The fold changes for
CXCL9, CXCL10, RIG-I, CD38, CD40, CD80, IL-12b, and IL-
23a were also plotted for graphical representation using Prism 5
software (GraphPad software Inc.).
2610
6 CD8+ or CD4+ T cells purified from elutriated
lymphocytes as above were treated with IFNAR2 antibody at
concentrations 0.03, 0.3, 3, or 30 mg/ml, plated in 12-well plates
and incubated for 2 h at 37uC. Next, IFNa2a was added to all cells
at 100 IU/ml, followed by incubation at 37uC. Cells were
harvested at 3, 6, and 18 h later, and total RNA was isolated
using RNeasy kit (Qiagen, CA). The mRNA expression of MX1
and ISG56 was investigated by QRT-PCR using TaqMan gene
expression assay primers and probe set and one step RT-PCR
master mix (Applied Biosystems). The 18S ribosomal RNA was
quantitated for all samples in triplicate, using TaqMan primers
and probe, and was used as endogenous control. The reactions
were run in triplicate in ABI 7900HT fast real-time PCR system
(Applied Biosystems) and analyzed with SDS 2.3 and RQ
Manager 1.2 softwares (Applied Biosystems). Quantitation of
MX1 expression in cells treated with IFNAR2 antibody and
IFNa2a was analyzed relative to the calibrator, i.e., cells treated
with IFNa2a in the absence of IFNAR2 antibody. The data is
presented as MX1 expression relative to the calibrator.
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Co-culture medium supernatants were analyzed for various
cytokines by ELISA. Supernatants from CD8+ T cells were
analyzed for IFNc and TNFa while those from CD4+ T cells were
assayed for IFNc, IL-4, IL-17, IL-2 and IL-12. All ELISAs were
performed with Quantikine colorimetric sandwich ELISA kits
(R&D Systems, Minneapolis, MN). DC supernatants were
analyzed for IFNa using IFNa multi-subtype ELISA kit (PBL
Interferon Source).
Statistical analyses
All data involving the comparison of wt RSV with its NS1 and/
or NS2 deletion mutants were analyzed for statistical significance
using repeated measures ANOVA with Tukey’s multiple compar-
ison post test (GraphPad Prism 5 software). In the experiments
involving blocking of IFNAR2 or adding exogenous IFN-I, paired
one-tailed T-test was used (GraphPad Prism 5 software). For all
statistical analyses data were considered significant at P,0.05.
Supporting Information
Figure S1 The NS1 protein reduces the MFI of CD103 in
CD8+ T cells (A), and increases the MFI of IL-4 in CD4+ T cells
(B). For A and B, the MFI is shown for proliferated cells positive
for the indicated markers of activation (shown on the top of each
panel) after their co-cultivation with autologous DC pre-infected
with the DNS1, DNS2 or DNS1/2 RSV deletion mutants, as
compared to cells from the same donors co-cultivated with DC
pre-infected with wt RSV, for which a value of 100% (dotted line)
has been assigned. Each symbol represents an individual donor
and the horizontal bars indicate mean values. For the DNS1 and
DNS1/2 viruses, significant differences to wt RSV are indicated by
letters: a, P,0.05; b, P,0.01.
Found at: doi:10.1371/journal.ppat.1001336.s001 (0.25 MB TIF)
Figure S2 Fluorescence-minus-one (FMO) controls for multi-
color staining of CD4+ T cells. A. Flow cytometry of cells stained
for CFSE and all cytokines except the one indicated at the top of
each panel. The figure demonstrates that omitting the antibody for
each cytokine results in a lack of detection of that cytokine in the
proliferating cells. B. Flow cytometry of cells stained for all
cytokines except IFNc or IL-4. Exclusion of staining of IFNc or
IL-4 results in lack of their detection, and the population positive
for both IFNc and IL-4 (the left panel) is detected only when cells
are stained with both the corresponding antibodies. The data
suggest that IFNc+IL-4+ cells indeed exist as a double positive
phenotype and are not a result of spectral overlap. C. Flow
cytometry analysis of IFNc or IL-17 FMO as performed in part B.
Found at: doi:10.1371/journal.ppat.1001336.s002 (0.66 MB TIF)
Table S1 Genes analyzed for transcription by QRT-PCR using
microfluidic gene card. The gene expression results are depicted in
figure 7.
Found at: doi:10.1371/journal.ppat.1001336.s003 (0.09 MB
DOC)
Acknowledgments
The authors thank Lijuan Yang for performing ELISAs and Thomas
McCarty for help with the microfluidic gene cards.
Author Contributions
Conceived and designed the experiments: SM PLC AB. Performed the
experiments: SM. Analyzed the data: SM PH CLN UJB RLR PLC AB.
Contributed reagents/materials/analysis tools: PH RLR PLC. Wrote the
paper: SM PLC AB. Contributed critically to this work; developed the co-
culture protocol, designed flow cytometry panels, optimized the polychro-
matic flow cytometry staining panels and participated critically in data
analysis by designing initial gating strategy, ensuring proper fluorochrome
compensation and providing guidance on FlowJo and SPICE analyses: PH.
References
1. Garcia-Sastre A, Egorov A, Matassov D, Brandt S, Levy DE, et al. (1998)
Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems.
Virology 252: 324–330.
2. Weber F, Haller O (2007) Viral suppression of the interferon system. Biochimie
89: 836–842.
3. Tough DF (2004) Type I interferon as a link between innate and adaptive
immunity through dendritic cell stimulation. Leuk Lymphoma 45: 257–264.
4. Fujita H, Asahina A, Tada Y, Fujiwara H, Tamaki K (2005) Type I interferons
inhibit maturation and activation of mouse Langerhans cells. J Invest Dermatol
125: 126–133.
5. von Hoegen P, Zawatzky R, Schirrmacher V (1990) Modification of tumor cells
by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific
cytolytic T cell activity via induction of interferon-alpha/beta. Cell Immunol
126: 80–90.
6. Thompson LJ, Kolumam GA, Thomas S, Murali-Krishna K (2006) Innate
inflammatory signals induced by various pathogens differentially dictate the
IFN-I dependence of CD8 T cells for clonal expansion and memory formation.
J Immunol 177: 1746–1754.
7. Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K (2005)
Type I interferons act directly on CD8 T cells to allow clonal expansion and
memory formation in response to viral infection. J Exp Med 202: 637–650.
8. Havenar-Daughton C, Kolumam GA, Murali-Krishna K (2006) Cutting Edge:
The direct action of type I IFN on CD4 T cells is critical for sustaining clonal
expansion in response to a viral but not a bacterial infection. J Immunol 176:
3315–3319.
9. Tough DF, Borrow P, Sprent J (1996) Induction of bystander T cell proliferation
by viruses and type I interferon in vivo. Science 272: 1947–1950.
10. Gallagher KM, Lauder S, Rees IW, Gallimore AM, Godkin AJ (2009) Type I
interferon (IFN alpha) acts directly on human memory CD4+ T cells altering
their response to antigen. J Immunol 183: 2915–2920.
11. Lachgar A, Bizzini B (1994) Involvement of alpha-interferon in HIV-1 induced
immunosuppression. A potential target for AIDS prophylaxis and treatment.
Biomed Pharmacother 48: 73–77.
12. Erickson S, Matikainen S, Thyrell L, Sangfelt O, Julkunen I, et al. (2002)
Interferon-alpha inhibits Stat5 DNA-binding in IL-2 stimulated primary T-
lymphocytes. Eur J Biochem 269: 29–37.
13. Schmidlin H, Dontje W, Groot F, Ligthart SJ, Colantonio AD, et al. (2006)
Stimulated plasmacytoid dendritic cells impair human T-cell development.
Blood 108: 3792–3800.
14. Zagury D, Lachgar A, Chams V, Fall LS, Bernard J, et al. (1998) Interferon
alpha and Tat involvement in the immunosuppression of uninfected T cells and
C-C chemokine decline in AIDS. Proc Natl Acad Sci U S A 95: 3851–3856.
15. Chi B, Dickensheets HL, Spann KM, Alston MA, Luongo C, et al. (2006) Alpha
and lambda interferon together mediate suppression of CD4 T cells induced by
respiratory syncytial virus. J Virol 80: 5032–5040.
16. Collins PL, Crowe JEJ (2007) Respiratory Syncytial Virus and Metapneumo-
virus. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA et al, eds.
Fields Virology. 5 ed. Philadelphia: Lippincott-Raven Publishers. pp 1601–1646.
17. Collins PL, Graham BS (2008) Viral and host factors in human respiratory
syncytial virus pathogenesis. J Virol 82: 2040–2055.
18. Hall CB, Walsh EE, Long CE, Schnabel KC (1991) Immunity to and frequency
of reinfection with respiratory syncytial virus. J Infect Dis 163: 693–698.
19. Henderson FW, Collier AM, Clyde WA, Jr., Denny FW (1979) Respiratory-
syncytial-virus infections, reinfections and immunity. A prospective, longitudinal
study in young children. N Engl J Med 300: 530–534.
20. Bukreyev A, Yang L, Fricke J, Cheng L, Ward JM, et al. (2008) The secreted
form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-
mediated restriction of replication by acting as an antigen decoy and through
effects on Fc receptor-bearing leukocytes. J Virol 82: 12191–12204.
21. Bossert B, Marozin S, Conzelmann KK (2003) Nonstructural proteins NS1 and
NS2 of bovine respiratory syncytial virus block activation of interferon
regulatory factor 3. J Virol 77: 8661–8668.
22. Elliott J, Lynch OT, Suessmuth Y, Qian P, Boyd CR, et al. (2007) Respiratory
syncytial virus NS1 protein degrades STAT2 by using the Elongin-Cullin E3
ligase. J Virol 81: 3428–3436.
23. Lo MS, Brazas RM, Holtzman MJ (2005) Respiratory syncytial virus
nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression
and alpha/beta interferon responsiveness. J Virol 79: 9315–9319.
24. Spann KM, Tran KC, Chi B, Rabin RL, Collins PL (2004) Suppression of the
induction of alpha, beta, and lambda interferons by the NS1 and NS2 proteins of
human respiratory syncytial virus in human epithelial cells and macrophages
[corrected]. J Virol 78: 4363–4369.
RSV NS1 Suppresses and Skews T Cell Response
PLoS Pathogens | www.plospathogens.org 15 April 2011 | Volume 7 | Issue 4 | e100133625. Spann KM, Tran KC, Collins PL (2005) Effects of nonstructural proteins NS1
and NS2 of human respiratory syncytial virus on interferon regulatory factor 3,
NF-kappaB, and proinflammatory cytokines. J Virol 79: 5353–5362.
26. Ling Z, Tran KC, Teng MN (2009) Human respiratory syncytial virus
nonstructural protein NS2 antagonizes the activation of beta interferon
transcription by interacting with RIG-I. J Virol 83: 3734–3742.
27. Bitko V, Shulyayeva O, Mazumder B, Musiyenko A, Ramaswamy M, et al.
(2007) Nonstructural Proteins of Respiratory Syncytial Virus Suppress
Premature Apoptosis by an NF-{kappa}B-Dependent, Interferon-Independent
Mechanism and Facilitate Virus Growth. J Virol 81: 1786–1795.
28. Munir S, Le Nouen C, Luongo C, Buchholz UJ, Collins PL, et al. (2008)
Nonstructural proteins 1 and 2 of respiratory syncytial virus suppress maturation
of human dendritic cells. J Virol 82: 8780–8796.
29. Varol C, Landsman L, Fogg DK, Greenshtein L, Gildor B, et al. (2007)
Monocytes give rise to mucosal, but not splenic, conventional dendritic cells.
J Exp Med 204: 171–180.
30. de Bree GJ, van Leeuwen EM, Out TA, Jansen HM, Jonkers RE, et al. (2005)
Selective accumulation of differentiated CD8+ T cells specific for respiratory
viruses in the human lung. J Exp Med 202: 1433–1442.
31. Xu Y, Zhan Y, Lew AM, Naik SH, Kershaw MH (2007) Differential
development of murine dendritic cells by GM-CSF versus Flt3 ligand has
implications for inflammation and trafficking. J Immunol 179: 7577–7584.
32. Farrar JD, Smith JD, Murphy TL, Leung S, Stark GR, et al. (2000) Selective loss
of type I interferon-induced STAT4 activation caused by a minisatellite insertion
in mouse Stat2. Nat Immunol 1: 65–69.
33. Rogge L, D’Ambrosio D, Biffi M, Penna G, Minetti LJ, et al. (1998) The role of
Stat4 in species-specific regulation of Th cell development by type I IFNs.
J Immunol 161: 6567–6574.
34. Le Floc’h A, Jalil A, Vergnon I, Le Maux Chansac B, Lazar V, et al. (2007)
Alpha E beta 7 integrin interaction with E-cadherin promotes antitumor CTL
activity by triggering lytic granule polarization and exocytosis. J Exp Med 204:
559–570.
35. Rihs S, Walker C, Virchow JC, Jr., Boer C, Kroegel C, et al. (1996) Differential
expression of alpha E beta 7 integrins on bronchoalveolar lavage T lymphocyte
subsets: regulation by alpha 4 beta 1-integrin crosslinking and TGF-beta.
Am J Respir Cell Mol Biol 15: 600–610.
36. Cepek KL, Shaw SK, Parker CM, Russell GJ, Morrow JS, et al. (1994) Adhesion
between epithelial cells and T lymphocytes mediated by E-cadherin and the
alpha E beta 7 integrin. Nature 372: 190–193.
37. Franciszkiewicz K, Le Floc’h A, Jalil A, Vigant F, Robert T, et al. (2009)
Intratumoral induction of CD103 triggers tumor-specific CTL function and
CCR5-dependent T-cell retention. Cancer Res 69: 6249–6255.
38. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, et al. (2003)
Sensitive and viable identification of antigen-specific CD8+ T cells by a flow
cytometric assay for degranulation. J Immunol Methods 281: 65–78.
39. Seder RA, Darrah PA, Roederer M (2008) T-cell quality in memory and
protection: implications for vaccine design. Nat Rev Immunol 8: 247–258.
40. Wong P, Pamer EG (2003) Feedback regulation of pathogen-specific T cell
priming. Immunity 18: 499–511.
41. Fukuda M (1991) Lysosomal membrane glycoproteins. Structure, biosynthesis,
and intracellular trafficking. J Biol Chem 266: 21327–21330.
42. Abu-Khabar KS, Armstrong JA, Ho M (1992) Type I interferons (IFN-alpha
and -beta) suppress cytotoxin (tumor necrosis factor-alpha and lymphotoxin)
production by mitogen-stimulated human peripheral blood mononuclear cell.
J Leukoc Biol 52: 165–172.
43. Liu AN, Mohammed AZ, Rice WR, Fiedeldey DT, Liebermann JS, et al. (1999)
Perforin-independent CD8(+) T-cell-mediated cytotoxicity of alveolar epithelial
cells is preferentially mediated by tumor necrosis factor-alpha: relative
insensitivity to Fas ligand. Am J Respir Cell Mol Biol 20: 849–858.
44. Ratner A, Clark WR (1993) Role of TNF-alpha in CD8+ cytotoxic T
lymphocyte-mediated lysis. J Immunol 150: 4303–4314.
45. Singh A, Suresh M (2007) A role for TNF in limiting the duration of CTL
effector phase and magnitude of CD8 T cell memory. J Leukoc Biol 82:
1201–1211.
46. Firestein GS, Roeder WD, Laxer JA, Townsend KS, Weaver CT, et al. (1989) A
new murine CD4+ T cell subset with an unrestricted cytokine profile. J Immunol
143: 518–525.
47. Hegazy AN, Peine M, Helmstetter C, Panse I, Frohlich A, et al. (2010)
Interferons direct Th2 cell reprogramming to generate a stable GATA-3(+)T-
bet(+) cell subset with combined Th2 and Th1 cell functions. Immunity 32:
116–128.
48. Zhu J, Paul WE (2010) CD4(+) T Cell Plasticity-Th2 Cells Join the Crowd.
Immunity 32: 11–13.
49. Bukreyev A, Belyakov IM, Prince GA, Yim KC, Harris KK, et al. (2005)
Expression of interleukin-4 by recombinant respiratory syncytial virus is
associated with accelerated inflammation and a nonfunctional cytotoxic T-
lymphocyte response following primary infection but not following challenge
with wild-type virus. J Virol 79: 9515–9526.
50. van der Velden VH, Laan MP, Baert MR, de Waal Malefyt R, Neijens HJ, et al.
(2001) Selective development of a strong Th2 cytokine profile in high-risk
children who develop atopy: risk factors and regulatory role of IFN-gamma, IL-4
and IL-10. Clin Exp Allergy 31: 997–1006.
51. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, et al. (2007)
Phenotypic and functional features of human Th17 cells. J Exp Med 204:
1849–1861.
52. Marijanovic Z, Ragimbeau J, van der Heyden J, Uze G, Pellegrini S (2007)
Comparable potency of IFNalpha2 and IFNbeta on immediate JAK/STAT
activation but differential down-regulation of IFNAR2. Biochem J 407:
141–151.
53. Izaguirre A, Barnes BJ, Amrute S, Yeow WS, Megjugorac N, et al. (2003)
Comparative analysis of IRF and IFN-alpha expression in human plasmacytoid
and monocyte-derived dendritic cells. J Leukoc Biol 74: 1125–1138.
54. Graham BS, Bunton LA, Wright PF, Karzon DT (1991) Role of T lymphocyte
subsets in the pathogenesis of primary infection and rechallenge with respiratory
syncytial virus in mice. J Clin Invest 88: 1026–1033.
55. Fishaut M, Tubergen D, McIntosh K (1980) Cellular response to respiratory
viruses with particular reference to children with disorders of cell-mediated
immunity. J Pediatr 96: 179–186.
56. Woodberry T, Suscovich TJ, Henry LM, August M, Waring MT, et al. (2005)
Alpha E beta 7 (CD103) expression identifies a highly active, tonsil-resident
effector-memory CTL population. J Immunol 175: 4355–4362.
57. Smyth LJ, Kirby JA, Cunningham AC (2007) Role of the mucosal integrin
alpha(E)(CD103)beta(7) in tissue-restricted cytotoxicity. Clin Exp Immunol 149:
162–170.
58. O’Quinn DB, Palmer MT, Lee YK, Weaver CT (2008) Emergence of the Th17
pathway and its role in host defense. Adv Immunol 99: 115–163.
59. Kolls JK, Linden A (2004) Interleukin-17 family members and inflammation.
Immunity 21: 467–476.
60. Wiehler S, Proud D (2007) Interleukin-17A modulates human airway epithelial
responses to human rhinovirus infection. Am J Physiol Lung Cell Mol Physiol
293: L505–515.
61. Fujisawa H (2008) Neutrophils play an essential role in cooperation with
antibody in both protection against and recovery from pulmonary infection with
influenza virus in mice. J Virol 82: 2772–2783.
62. Sporri R, Joller N, Hilbi H, Oxenius A (2008) A novel role for neutrophils as
critical activators of NK cells. J Immunol 181: 7121–7130.
63. Pepper M, Linehan JL, Pagan AJ, Zell T, Dileepan T, et al. (2010) Different
routes of bacterial infection induce long-lived TH1 memory cells and short-lived
TH17 cells. Nat Immunol 11: 83–89.
64. Kohyama S, Ohno S, Isoda A, Moriya O, Belladonna ML, et al. (2007) IL-23
enhances host defense against vaccinia virus infection via a mechanism partly
involving IL-17. J Immunol 179: 3917–3925.
65. McKinstry KK, Strutt TM, Buck A, Curtis JD, Dibble JP, et al. (2009) IL-10
deficiency unleashes an influenza-specific Th17 response and enhances survival
against high-dose challenge. J Immunol 182: 7353–7363.
66. Becker Y (2006) Respiratory syncytial virus (RSV) evades the human adaptive
immune system by skewing the Th1/Th2 cytokine balance toward increased
levels of Th2 cytokines and IgE, markers of allergy–a review. Virus Genes 33:
235–252.
67. Miyairi I, DeVincenzo JP (2008) Human genetic factors and respiratory
syncytial virus disease severity. Clin Microbiol Rev 21: 686–703.
68. Choi EH, Lee HJ, Yoo T, Chanock SJ (2002) A common haplotype of
interleukin-4 gene IL4 is associated with severe respiratory syncytial virus disease
in Korean children. J Infect Dis 186: 1207–1211.
69. Hoebee B, Rietveld E, Bont L, Oosten M, Hodemaekers HM, et al. (2003)
Association of severe respiratory syncytial virus bronchiolitis with interleukin-4
and interleukin-4 receptor alpha polymorphisms. J Infect Dis 187: 2–11.
70. Ermers MJ, Hoebee B, Hodemaekers HM, Kimman TG, Kimpen JL, et al.
(2007) IL-13 genetic polymorphism identifies children with late wheezing after
respiratory syncytial virus infection. J Allergy Clin Immunol 119: 1086–1091.
71. Forton JT, Rowlands K, Rockett K, Hanchard N, Herbert M, et al. (2009)
Genetic association study for RSV bronchiolitis in infancy at the 5q31 cytokine
cluster. Thorax 64: 345–352.
72. Zhang W, Yang H, Kong X, Mohapatra S, San Juan-Vergara H, et al. (2005)
Inhibition of respiratory syncytial virus infection with intranasal siRNA
nanoparticles targeting the viral NS1 gene. Nat Med 11: 56–62.
73. Parronchi P, De Carli M, Manetti R, Simonelli C, Sampognaro S, et al. (1992)
IL-4 and IFN (alpha and gamma) exert opposite regulatory effects on the
development of cytolytic potential by Th1 or Th2 human T cell clones.
J Immunol 149: 2977–2983.
74. Brinkmann V, Geiger T, Alkan S, Heusser CH (1993) Interferon alpha increases
the frequency of interferon gamma-producing human CD4+ T cells. J Exp Med
178: 1655–1663.
75. Lopez CB, Garcia-Sastre A, Williams BR, Moran TM (2003) Type I interferon
induction pathway, but not released interferon, participates in the maturation of
dendritic cells induced by negative-strand RNA viruses. J Infect Dis 187:
1126–1136.
76. Berghall H, Siren J, Sarkar D, Julkunen I, Fisher PB, et al. (2006) The
interferon-inducible RNA helicase, mda-5, is involved in measles virus-induced
expression of antiviral cytokines. Microbes Infect 8: 2138–2144.
77. Padovan E, Spagnoli GC, Ferrantini M, Heberer M (2002) IFN-alpha2a induces
IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic
cells and enhances their capacity to attract and stimulate CD8+ effector T cells.
J Leukoc Biol 71: 669–676.
RSV NS1 Suppresses and Skews T Cell Response
PLoS Pathogens | www.plospathogens.org 16 April 2011 | Volume 7 | Issue 4 | e100133678. Wuest T, Austin BA, Uematsu S, Thapa M, Akira S, et al. (2006) Intact TRL 9
and type I interferon signaling pathways are required to augment HSV-1
induced corneal CXCL9 and CXCL10. J Neuroimmunol 179: 46–52.
79. Kaiko GE, Horvat JC, Beagley KW, Hansbro PM (2008) Immunological
decision-making: how does the immune system decide to mount a helper T-cell
response? Immunology 123: 326–338.
80. Bettelli E, Korn T, Oukka M, Kuchroo VK (2008) Induction and effector
functions of T(H)17 cells. Nature 453: 1051–1057.
81. McRae BL, Semnani RT, Hayes MP, van Seventer GA (1998) Type I IFNs
inhibit human dendritic cell IL-12 production and Th1 cell development.
J Immunol 160: 4298–4304.
82. Rudd BD, Luker GD, Luker KE, Peebles RS, Lukacs NW (2007) Type I
interferon regulates respiratory virus infected dendritic cell maturation and
cytokine production. Viral Immunol 20: 531–540.
83. Hussell T, Baldwin CJ, O’Garra A, Openshaw PJ (1997) CD8+ T cells control
Th2-driven pathology during pulmonary respiratory syncytial virus infection.
Eur J Immunol 27: 3341–3349.
84. Srikiatkhachorn A, Braciale TJ (1997) Virus-specific CD8+ T lymphocytes
downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia
during experimental murine respiratory syncytial virus infection. J Exp Med 186:
421–432.
85. Culley FJ, Pollott J, Openshaw PJ (2002) Age at first viral infection determines
the pattern of T cell-mediated disease during reinfection in adulthood. J Exp
Med 196: 1381–1386.
86. Le Nouen C, Hillyer P, Munir S, Winter CC, McCarty T, et al. (2010) Effects of
human respiratory syncytial virus, metapneumovirus, parainfluenza virus 3 and
influenza virus on CD4+ T cell activation by dendritic cells. PLoS One 5:
e15017.
87. Murphy BR, Sotnikov AV, Lawrence LA, Banks SM, Prince GA (1990)
Enhanced pulmonary histopathology is observed in cotton rats immunized with
formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein
and challenged with RSV 3-6 months after immunization. Vaccine 8: 497–502.
88. Schuurhuis DH, Fu N, Ossendorp F, Melief CJ (2006) Ins and outs of dendritic
cells. Int Arch Allergy Immunol 140: 53–72.
89. Le Nouen C, Hillyer P, Munir S, Winter CC, McCarty T, et al. (2010) Effects of
human respiratory syncytial virus, metapneumovirus, parainfluenza virus 3 and
influenza virus on CD4+ T cell activation by dendritic cells. PLoS One 5:
e15017.
90. Jaks E, Gavutis M, Uze G, Martal J, Piehler J (2007) Differential receptor
subunit affinities of type I interferons govern differential signal activation. J Mol
Biol 366: 525–539.
RSV NS1 Suppresses and Skews T Cell Response
PLoS Pathogens | www.plospathogens.org 17 April 2011 | Volume 7 | Issue 4 | e1001336